Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond

Biological Psychiatry

Volumn 60, Issue 2, 2006, Pages 141-151

  Tunbridge, Elizabeth M ^a   Harrison, Paul J ^a   Weinberger, Daniel R ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Catecholamine; dopamine; prefrontal cortex; schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; METHIONINE; VALINE;

BRAIN FUNCTION; BRAIN REGION; COGNITION; COGNITIVE DEFECT; EMOTION; ENZYME ACTIVITY; ENZYMOLOGY; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; NEUROBIOLOGY; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; WORKING MEMORY;

AMINO ACID SUBSTITUTION; CATECHOL O-METHYLTRANSFERASE; CATECHOLAMINES; COGNITION; HUMANS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 33745703902     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2005.10.024     Document Type: Review

References (112)

1. Akil M., Kolachana B.S., Rothmond D.A., Hyde T.H., Weinberger D.R., and Kleinman J.E. Catechol-o-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 23 (2003) 2008-2013
2. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 58 (1999) 315-348
3. Avramopoulos D., Stefanis N.C., Hantoumi I., Smyrnis N., and Evdokidimis Stefanis C.N. Higher scores of self reported schizotypy in healthy young men carrying the COMT high activity allele. Mol Psychiatry 7 (2002) 706-711
4. Axelrod J., and Tomchick R. Enzymatic o-methylation of epinephrine and other catechols. J Biol Chem 233 (1958) 702-705
5. Badner J.A., and Gershon E.S. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 7 (2002) 405-411
6. Baker K., Baldeweg T., Sivagnanasundaram S., Scambler P., and Skuse D. COMT Val108/158Met modifies mismatch negativity and cognitive function in 22q11 deletion syndrome. Biol Psychiatry 58 (2005) 23-31
7. Bassett A.S., and Chow E.W.C. 22q11 deletion syndrome. A genetic subtype of schizophrenia. Biol Psychiatry 46 (1999) 882-891
8. Bassett A.S., Hodgkinson K., Chow E.W.C., Correia S., Scott L.E., and Weksberg R. 22q11 deletion syndrome in adults with schizophrenia. Am J Med Genet (Neuropsychiatr Genet) 81 (1998) 328-337
9. Bearden C.E., Jawad A.F., Lynch D.R., Sokol S., Kanes S.J., McDonald-McGinn D.M., et al. Effects of a functional COMT polymorphism on prefrontal cognitive function in patients with 22q11 deletion syndrome. Am J Psychiatry 161 (2004) 1700-1702
10. Bellgrove M.A., Domschke K., Hawi Z., Kirley A., Mullins C., Robertson I.H., et al. The methionine allele of the COMT polymorphism impairs prefrontal cognition in children and adolescents with ADHD. Exp Brain Res 163 (2005) 352-360
11. Bertocci B., Miggiano V., Da Prada M., Dembic Z., Lahm H.-W., and Malherbe P. Human catechol-omethyltransferase. Cloning and expression of the membrane-associated form. Proc Natl Acad Sci U S A 88 (1991) 1416-1420
12. Bertolino A., Caforio G., Blasi G., De Candia M., Latorre V., Petruzzella V., et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 161 (2004) 1798-1805
13. 158Met polymorphism in chronic schizophrenia. Biol Psychiatry 52 (2002) 701-707
14. Bilder R.M., Volavka J., Lachman H.M., and Grace A.A. The catechol-o-methyltransferase polymorphism. Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29 (2004) 1943-1961
15. 158met genotype on attentional control. J Neurosci 25 (2005) 5038-5045
16. Borroni B., Agosti C., Archetti S., Costanzi C., Bonomi S., Ghianda D., et al. Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer disease. Neurosci Lett 370 (2004) 127-129
17. Bray N.J., Buckland P.R., Williams N.M., Williams H.J., Norton N., Owen M.J., et al. A haplotype implicated in schizophrenia is associated with reduced COMT expression in human brain. Am J Hum Genet 73 (2003) 152-161
18. Broch Jr. O.J., and Fonnum F. The regional and subcellular distribution of catechol-o-methyltransferse in the rat brain. J Neurochemistry 19 (1972) 2049-2055
19. Busch A.E., Karbach U., Miska D., Gorboulev V., Akhoundova A., Volk C., et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54 (1998) 342-352
20. Carr D.B., and Sesack S.R. Projections from the rat prefrontal cortex to the ventral tegmental area. Target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 20 (2001) 3864-3873
21. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene. longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57 (2005) 1117-1127
22. 8F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 43 (2002) 201-207
23. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT). Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75 (2004) 807-821
24. Chen X., Wang X., O'Neill A.F., Walsh D., and Kendler K.S. Variants in the catechol-o-methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families. Mol Psychiatry 9 (2004) 962-967
25. Coon H., Jensen S., Holik J., Hoff M., Myles-Worsley M., Reimherr F., et al. Genomic scan for genes predisposing to schizophrenia. Am J Med Genet (Neuropsychiatr Genet) 54 (1994) 59-71
26. Diamond A., Briand L., Fossella J., and Gehlbach L. Genetic and neurochemical modulation of prefrontal cognitive function in children. Am J Psychiatry 161 (2004) 125-132
27. 158met genotype and neural mechanisms of arousal and behavioral regulation. Arch Gen Psychiatry.
28. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98 (2001) 6917-6922
29. Enoch M.A., Xu K., Ferro E., Harris C.R., and Goldman D. Genetic origins of anxiety in women. A role for a functional catechol-O-methyltransferase polymorphism. Psychiatr Genet 13 (2003) 33-41
30. Fan J.B., Chen W.Y., Tang J.X., Li S., Gu N.F., Feng G.Y., et al. Family-based association studies of COMT gene polymorphisms and schizophrenia in the Chinese population. Mol Psychiatry 7 (2005) 446-452
31. Floderus Y., Ross S.B., and Wetterberg L. Erythrocyte catechol-o-methyltransferase activity in a Swedish population. Clin Genet 19 (1981) 389-392
32. 158Met polymorphism. Mov Disord 19 (2004) 885-891
33. 108/158Met) gene polymorphism with prefrontal P300 during information processing. Biol Psychiatry 54 (2003) 40-48
34. Glatt S.J., Faraone S.V., and Tsuang M.T. Association between a functional catechol-o-methyltransferase gene polymorphism and schizophrenia. Meta-analysis of case-control and family-based studies. Am J Psychiatry 160 (2003) 469-476
35. Gogos J.A., Morgan M., Luine V., Ogawa S., Pfaff D., and Karayiourgou M. Catechol-o-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behaviour. Proc Natl Acad Sci U S A 95 (1998) 9991-9996
36. Goldberg T.E., Egan M.F., Gscheidle T., Coppola R., Weickert T., Kolachana B.S., et al. Executive subprocesses in working memory. relationship to catechol-o-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 60 (2003) 889-896
37. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., and Williams G.V. Targeting the dopamine D1 receptor in schizophrenia. Insights for cognitive dysfunction. Psychopharmacology (Berl) 174 (2001) 3-16
38. 1 receptors in prefrontal cells and circuits. Brain Res Rev 31 (2000) 295-301
39. Gothelf D., Eliez S., Thompson T., Hinard C., Penniman L., Feinstein C., et al. COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat Neurosci 8 (2005) 1500-1502
40. Gothelf D., Firsh A., Munitz H., Rockah R., Aviram A., Mozes T., et al. Velocardiofacial manifestations and microdeletions in schizophrenic inpatients. A Med Genet (Neuropsychiatr Genet) 72 (1997) 455-461
41. Grace A.A. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm Gen Sect 91 (1993) 111-134
42. Grace A.A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Brain Res Rev 31 (2000) 330-341
43. Grossman M.H., Creveling C.R., Rybczynski R., Braverman M., Isersky C., and Breakefield X.O. Soluble and particulate forms of rat catechol-O-methyltransferase distinguished by gel electrophoresis and immune fixation. J Neurochem 44 (1985) 421-432
44. Grossman M.H., Emanuel B.S., and Budarf M.L. Chromosomal mapping of the human catechol-o-methyltransferase gene to 22q11.1 → 22q11.2. Genomics 12 (1992) 822-825
45. Haber S.N., and Fudge J.L. The interface between dopamine neurons and the amygdala. Implications for schizophrenia. Schizophr Bull 23 (1997) 471-482
46. Hong J., Shu-Leong H., Tao X., and Lap-ping Y. Distribution of catechol-o-methyltransferase expression in human central nervous system. NeuroReport 9 (1998) 2861-2864
47. Horowitz A., Shifman S., Rivlin M., Pisanté A., and Darvasi A. A survey of the 22q11 microdeletion in a large cohort of schizophrenic patients. Schizophr Res 73 (2005) 263-267
48. Huotari M., Gogos J.A., Karayiorou M., Koponen O., Forsberg M., Raasmaja A., et al. Brain catecholamine metabolism in catechol-o-methyltransferase (COMT)-deficient mice. Eur J Neurosci 15 (2002) 246-256
49. Jiang H., Xie T., Ramsden D.B., and Ho S.L. Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology 45 (2003) 1011-1018
50. Joober R., Gauthier J., Lal S., Bloom D., Lalonde P., Rouleau G., et al. Catechol-o-methyltransferase Val-108/158-Met gene variants associated with performance on the Wisconsin Card Sorting Test. Arch Gen Psychiatry 59 (2002) 662-663
51. Karayiorgou M., Altemus M., Galke B.L., Goldman D., Murphy D.L., Ott J., et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci U S A 94 (1997) 4572-4575
52. Karayiorgou M., Morris M.A., Morrow B., Shprintzen R.J., Goldberg R., Borrow J., et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci U S A 92 (1995) 7612-7616
53. Karhunen T., Tilgmann C., Ulmanen I., Julkunen I., and Panula P. Distribution of catechol-o-methyltransferase enzyme in rat tissue. J Histochem Cytochem 42 (1994) 1079-1090
54. Karoum F., Chrapusta S.J., and Egan M.J. 3-methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex. Reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens and striatum by a simple two-pool model. J Neurochem 63 (1994) 972-979
55. Kastner A., Anglade P., Bounaix C., Damier P., Javoy-Agid F., Bromet N., et al. Immunohistochemical study of catechol-o-methyltransferase in the human mesostriatal system. Neuroscience 62 (1994) 449-457
56. Kopin I.J. Catecholamine metabolism. basic aspects and clinical significance. Pharmacol Rev 37 (1985) 333-364
57. Lachman H.M., Papoulos D.F., Saito T., Yu Y.-M., Szumlanski C.L., and Weinshilboum R.M. Human catechol-o-methyltransferase pharmacogenetics. Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6 (1996) 243-250
58. Lavigne J.A., Helzlsouer K.J., Huang H.Y., Strickland P.T., Bell D.A., Selmin O., et al. An association between the allele coding for a low activity variant of catechol-o-methyltransferase and the risk for breast cancer. Cancer Res 57 (1997) 5493-5497
59. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part 2. schizophrenia. Am J Hum Genet 73 (2003) 34-48
60. Lewis D.A., Melchiztky D.S., Sesack S.R., Whitehead R.E., Auh S., and Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex. Regional, laminar and ultrastructural localization. J Comp Neurol 432 (2001) 119-136
61. Li T., Ball D., Zhao J., Murray R.M., Liu X., Sham P.C., et al. Family-based linkage disequilibrium mapping using SNP marker haplotypes. Application to a potential locus for schizophrenia at chromosome 22q11. Mol Psychiatry 5 (2000) 77-84
62. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melén K., Julkunen I., et al. Kinetics of human soluble and membrane-bound catechol-o-methyltransferase. A revised mechanism of the thermolabile variant of the enzyme. Biochemistry 34 (1995) 4202-4210
63. Lundström K., Salminen M., Jalanko A., Savolainen R., and Ulmanen I. Cloning and characterization of human placental catechol-o-methyltransferase cDNA. DNA Cell Biol 10 (1991) 181-189
64. Lundström K., Tenhunen J., Tilgmann C., Karhunen T., Panula P., and Ulmanen I. Cloning, expression and structure of catechol-o-methyltransferase. Biochim Biophys Acta 16 (1995) 1-10
65. Maj J., Rogóz Z., Skuza G., Sowinska H., and Superata J. Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J Neural Trans 2 (1990) 101-112
66. Malholtra A.K., Kestler L.J., Mazzanti C., Bates J.A., Goldberg T., and Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 159 (2002) 652-654
67. Männistö P.T., and Kaakkola S. Catechol-o-methyltransferase (COMT). biochemistry, molecular biology, pharmacology and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51 (1999) 593-628
68. Matsumoto M., Shannon Weickert C., Akil M., Lipska B.K., Hyde T.M., Herman M.M., et al. Catechol-o-methyltransferase mRNA expression in human and rat brain. Evidence for a role in cortical neuronal function. Neuroscience 116 (2003) 127-137
69. Matsumoto M., Shannon Weickert C., Beltaifa S., Kolachana B., Chen J., Hyde T.M., et al. Catechol-o-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology 28 (2003) 1521-1530
70. 158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 100 (2003) 6186-6191
71. Mattay V.S., Tessitore A., Callicott J.H., Bertolino A., Goldberg T.E., Chase T.N., et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 51 (2002) 156-164
72. Maynard T.M., Haskell G.T., Lieberman J.A., and LaMantia A.-S. 22q11 DS. Genomic mechanisms and gene function in DiGeorge/velocardiofacial syndrome. Int J Dev Neurosci 20 (2002) 407-419
73. McTavish S.F., Cowen P.J., and Sharp T. Effect of a tyrosine-free amino acid mixture on regional brain catecholamine synthesis and release. Psychopharmacology (Berl) 141 (1999) 182-188
74. Meyer-Lindenberg A., Kohn P.D., Kolachana B., Kippenham S., McInerney-Leo A., Nussbaum R., et al. Midbrain dopamine and prefrontal function in humans. interaction and modulation by COMT genotype. Nat Neurosci 8 (2005) 594-596
75. Miner L.H., Schroeter S., Blakeley R.D., and Sesack S.R. Ultrastructural localization of the norepinephine transporter in the superficial and deep layers in the rat prelimbic prefrontal cortex and its relationship to probable dopamine terminals. J Comp Neurol 466 (2003) 478-494
76. Munafo M.R., Bowes L., Clark T.G., and Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia. A meta-analysis of case-control studies. Mol Psychiatry 10 (2005) 765-770
77. Murphy K.C., Jones L.A., and Owen M.J. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56 (1999) 940-945
78. Napolitano A., Bellini G., Borroni E., Zürcher G., and Bonuccelli U. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine. a microdialysis study in freely moving rats. Parkinsonism Relat Disord 9 (2003) 145-150
79. Nicodemus K.K., Straub R.E., Egan M.F., and Weinberger D.R. Evidence for statistical epistasis between (COMT) Val158Met polymorphism and multiple putative schizophrenia susceptibility genes. Am J Med Genet 138B (2005) 130-131
80. Nolan K.A., Bilder R.M., Lachman H.M., and Volavka J. Catechol-o-methyltransferase Val158Met polymorphism in schizophrenia. Differential effect of Val and Met alleles on cognitive stability and flexibility. Am J Psychiatry 161 (2004) 359-361
81. Palmitier M.A., Kang A.M., and Kidd K.K. Global variation in the frequencies of functionally different catechol-o-methyltransferase alleles. Biol Psychiatry 46 (1999) 557-567
82. Paylor R., McIlwain K.L., McAninch R., Nellis A., Yuva-Paylor L.A., Baldini A., et al. Mice deleted for the DiGeorge/velocardiofacial syndrome region show abnormal sensorimotor gating and learning and memory impairments. Hum Mol Genet 10 (2001) 2645-2650
83. Raxworthy M.J., Gulliver P.A., and Hughes P.J. The cellular location of catechol-O-methyltransferase in rat liver. Naunyn Schmiedebergs Arch Pharmacol 320 (1982) 182-188
84. Rosenberg D.R., and Lewis D.A. Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices. A tyrosine hydroxylase immunohistochemical analysis. J Comp Neurol 358 (1995) 383-400
85. Roth J.A. Membrane-bound catechol-o-methyltransferase. A reevaluation of its role in the o-methylation of the catecholamine neurotransmitters. Rev Physiol Biochem Pharmacol 120 (1992) 1-29
86. Sasaki M., Kaneuchi M., Sakuragi N., and Dahiya R. Multiple promoters of catechol-o-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Res 63 (2003) 3101-3106
87. Sawaguchi T., and Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex. Involvement in working memory. Science 251 (1991) 947-950
88. Seamans J.K., and Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74 (2004) 1-58
89. Sesack S.R., Hawrylak V.A., Matus C., Guido M.A., and Levey A.I. Dopamine axon varicositites in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 18 (1998) 2697-2708
90. Shifman S., Bronstein M., Sternfeld M., Pisante-Shalom A., Lev-Lehman E., Weizman A., et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 71 (2002) 1296-1302
91. Shprintzen R.J., Goldberg R.B., Lewin M.L., Sidoti E.J., Berkman M.D., Argamaso R.V., et al. A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities. Velo-cardio-facial syndrome. Cleft Palate J 5 (1978) 56-62
92. Smolka M.N., Schumann G., Wrase J., Grüsser S.M., Flor H., Mann K., et al. J Neurosci 25 (2005) 836-842
93. Stefanis N.C., Van Os J., Avramopoulos D., Smyrnis N., Evdokimidis I., Hantoumi I., et al. Variation in catechol-o-methyltransferase val158 met genotype associated with schizotypy but not cognition. A population study in 543 young men. Biol Psychiatry 56 (2004) 510-515
94. Sweet R.A., Devlin B., Pollock B.G., Sukonick D.L., Kastango K.B., Bacanu S.A., et al. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Mol Psychiatry 10 (2005) 1026-1036
95. Tenhunen J., Salminen M., Lundström K., Kiviluoto T., Savolainen R., and Ulmanen I. Genomic organization of the human catechol-o-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 223 (1994) 1049-1059
96. Thierry A.-M., Tassin J.P., Blanc G., and Glowinski J. Selective activation of the mesocortical dopamine system by stress. Nature 263 (1976) 242-244
97. Tunbridge E.M., Bannerman D.M., Sharp T., and Harrison P.J. Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci 24 (2004) 5331-5335
98. Tunbridge E., Burnet P.W., Sodhi M.S., and Harrison P.J. Catechol-o-methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex of schizophrenia, bipolar disorder and major depression. Synapse 51 (2004) 112-118
99. Tunbridge E.M., Weickert C.S., Kleinman J.E., Herman M.M., Chen J., Kolachana B.S., et al. Catechol-o-methyltransferase enzyme activity and protein expression in human prefrontal cortex across the postnatal life span program no. 675.17. 2005 Abstract Viewer/Itinerary Planner (2005), Society for Neuroscience, Washington, DC 2005. Online.
100. Tunbridge EM, Weinberger DR, Harrison PJ (in press): A novel protein isoform of catechol O-methyltransferase (COMT): Brain expression analysis in schizophrenia and bipolar disorder and effect of Val(158)Met genotype. Mol Psychiatry.
101. Ulmanen I., Peränen J., Tenhunen J., Tilgmann C., Karhunen T., Panula P., et al. Expression and intracellular localisation of catechol-o-methyltransferase in transfected mammalian cells. Eur J Biochem 243 (1997) 452-459
102. Weickert T.W., Goldberg T.E., Mishara A., Apud J.A., Kolachana B.S., Egan M.F., et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 56 (2004) 677-682
103. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44 (1987) 660-668
104. Weinberger D.R., Egan M.F., Bertolino A., Callicott J.H., Mattay V.S., Lipska B.K., et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50 (2001) 825-844
105. Williams G.V., and Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376 (1995) 572-575
106. Winterer G, Egan MF, Kolachana BS, Goldberg TE, Coppola R, Weinberger DR (in press): Prefrontal electrophysiological "noise" and COMT genotype in schizophrenia. Biol Psychiatry.
107. Winterer G., and Weinberger D.R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci 27 (2004) 683-690
108. Woo J.M., Yoon K.S., Choi Y.H., Oh K.S., Lee Y.S., and Yu B.H. The association between panic disorder and the L/L genotype of catechol-O-methyltransferase. J Psychiatr Res 38 (2004) 365-370
109. Xie T., Ho S.L., and Ramsden D.B. Characterization and implications of estrogenic down-regulation of human catechol-o-methyltransferase gene transcription. Mol Pharmacol 56 (1999) 31-38
110. Yan W., Jacobsen L.K., Krasnewich D.M., Guan X.-Y., Lenane M.C., Paul S.P., et al. Chromosome 22q11.2 interstitial deletions among childhood-onset schizophrenics and "multidimensionally impaired.". Am J Med Genet B Neuropsychiatr Genet 81 (1998) 41-43
111. Zahrt J., Taylor J.R., Mathew R.G., and Arnsten A.F.T. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 17 (1997) 8528-8535
112. Zubieta J.K., Heitzeg M.M., Smith Y.R., Bueller J.A., Xu K., Xu Y., et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299 (2003) 1240-1243